Phase II trial of brain MRI surveillance in stage IV breast cancer
Neuro-Oncology · 2025
DOI: 10.1093/neuonc/noaf018 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Neuro-Oncology, 2025. Verfasst von Kamran A Ahmed und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Moffitt Cancer Center, Tampa, Florida, USA. Hauptthemen laut MEDLINE: Brain, Brain Neoplasms, Breast Neoplasms, Magnetic Resonance Imaging. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Florida Breast Cancer Foundation.
Abstract (Originalsprache)
Background
Screening of asymptomatic stage IV breast cancer with brain MRIs is currently not recommended by National Comprehensive Cancer Network Guidelines. The incidence of asymptomatic brain metastasis is not well documented.
Methods
The study is designed as a single-arm, phase II trial, with the goal of investigating surveillance brain MRIs in neurologically asymptomatic patients with metastatic breast cancer. Breast cancer patients were classified into triple-negative (TN), HER2+, and hormone receptor (HR)+/HER2−. Patients underwent a surveillance brain MRI and a second brain MRI at 6 months if the baseline MRI was negative. Asymptomatic, stage IV breast cancer patients, ECOG ≤ 2, and life expectancy ≥ 6 months were eligible. The primary objective was to determine the frequency of asymptomatic brain metastasis in metastatic breast cancer. Clinical trial information: NCT05115474.
Results
A total of 101 patients completed the surveillance brain MRI including 40 HR+/HER2−, 33 HER2+, and 28 TN patients. The overall frequency of brain metastasis on initial surveillance brain MRI was 14% (n = 14) with rates of 18%, 15%, and 10% in TN, HER2+, and HR+/HER2− patients, respectively. Following the 6-month MRI, the cumulative rates of brain metastasis increased to 25% in TN, 24% in HER2+, and 23% in HR+/HER2− patients.
Conclusions
The highest frequency of brain metastases at baseline was in TN and HER2+ breast cancer. Following the 6-month MRI, the cumulative frequency was approximately a quarter across all subtypes. These results warrant confirmatory trials to refine brain MRI surveillance recommendations for neurologically asymptomatic stage IV breast cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, Moffitt Cancer Center, Tampa, Florida, USA.
- Department of Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa, Florida, USA.
- Department of Breast Oncology, Moffitt Cancer Center, Tampa, Florida, USA.
- Department of Radiology, Moffitt Cancer Center, Tampa, Florida, USA.
- Department of Senior Adult Oncology, Moffitt Cancer Center, Tampa, Florida, USA.
- Department of Neuro Oncology, Moffitt Cancer Center, Tampa, Florida, USA.
ORCID-Profile: Kamran A Ahmed, Martine Extermann
Förderung
- Florida Breast Cancer Foundation
Zitieren
APA
Ahmed, K. A., Kim, Y., Armaghani, A. J., Arrington, J. A., Costa, R. L., Czerniecki, B. J., Diaz, R., Dowell, R. A., Extermann, M., Forsyth, P. A., Lee, K. T., Loftus, L., Mills, M. N., Phuoc, V. H., Rosa, M., Soliman, H. H., Sam, C. S., Washington, I. R., Soyano, A. E., & Han, H. S. (2025). Phase II trial of brain MRI surveillance in stage IV breast cancer. Neuro-Oncology. https://doi.org/10.1093/neuonc/noaf018
Vancouver
Ahmed KA, Kim Y, Armaghani AJ, Arrington JA, Costa RL, Czerniecki BJ, et al. Phase II trial of brain MRI surveillance in stage IV breast cancer. Neuro-Oncology. 2025. doi:10.1093/neuonc/noaf018
BibTeX
@article{Ahmed2025,
author = {Ahmed, Kamran A and Kim, Youngchul and Armaghani, Avan J and Arrington, John A and Costa, Ricardo L and Czerniecki, Brian J and Diaz, Roberto and Dowell, Robin A and Extermann, Martine and Forsyth, Peter A and Lee, Kimberley T and Loftus, Loretta and Mills, Matthew N and Phuoc, Vania H and Rosa, Marilin and Soliman, Hatem H and Sam, Christine S and Washington, Iman R and Soyano, Aixa E and Han, Hyo S},
title = {Phase II trial of brain MRI surveillance in stage IV breast cancer},
journal = {Neuro-Oncology},
year = {2025},
doi = {10.1093/neuonc/noaf018}
}
EUVIMED